Monetary Cost of Alzheimer's Disease in China
2020年5月7日 更新者:Jianping Jia、Beijing Friendship Hospital
Monetary Cost of Alzheimer's Disease in China: Study Protocol for a Cluster Randomized Observational Study
The purpose of the study is to estimate the Chinese economic burden in patients with Alzheimer's Disease (AD).
研究概览
详细说明
This observational study covered all the 30 provincials/municipals/autonomous in mainland China except Hong Kong and Macau.
Tier 3 hospitals, psychiatric hospitals, elderly hospitals, nursing home and communities were randomly selected as research centers, and more than 2500 patients with AD and their caregivers were enrolled at last.
The main outcome of this study was assessed not only by the electronic medical system of communities and hospitals, but also by questionnaires.
Using a societal prevalence-based gross COI approach to estimated the total yearly costs of AD in China.
研究类型
观察性的
注册 (实际的)
3098
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Beijing
-
Beijing、Beijing、中国、100053
- Xuanwu Hospital, Capital Medical University
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
60年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
取样方法
概率样本
研究人群
Patients with Alzhemer's disease and their caregivers.
描述
Inclusion Criteria:
- New patients who are diagnosed with AD in this investigation or old patients who were diagnosed prior to this investigation were eligible;
- AD diagnosis must meet criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA). The diagnosis should also meet the following: Modified Hachinski Ischemic Scale (MHIS) score≤4, Activity of Daily Living Scale (ADL) score≥23, Geriatric Depression Scale (GDS) score<11. Neuroimaging MRI support AD diagnosis (exist atrophy in medial temporal lobe, white matter lesions score≤2 minutes according to the Fazekas criteria. AD disease classification according to mini-mental state examination (MMSE) scale (for illiterate dementia: mild: 21~24 points; moderate: 11~20 points; severe: 10 points or less; for lettered dementia: mild: 16~19 points; moderate: 8~15 points; severe: 7 points or less). The diagnosis of AD was confirmed by brain CT or MRI scans and by laboratory tests to rule out any other significant comorbidity.
- 60-year-old and above, men or women.
- Normal vision or corrected visual, normal audition or corrected auditory, and cooperate with inspections and treatments.
- Consent to participate with a signed informed consent by himself/herself or guardians.
Exclusion Criteria:
- Patient with vascular dementia or dementia caused by other reasons, such as major depression or other major psychiatric illnesses, thyroid dysfunction, encephalitis, multiple sclerosis, and other dementia which includes frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and Parkinson's dementia (PDD).
- MRI and laboratory tests (blood cell counts, liver and renal function, electrolyte, vitamin B12/folic, HIV, syphilis, and so on) do not support or rule out AD diagnoses.
- Has a history of alcoholism and drug abuse.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The Annual National Total Socioeconomic Cost for All AD Patients in China
大体时间:one year
|
The annual national total socioeconomic cost for all patients with AD in China in 2015 was obtained, with the average annual cost per patient with AD from our results multiplied by the all number of patients with AD in 2015.
So, the value reported in the data table below represents the total cost for all all participants in China.
|
one year
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 学习椅:Jia Jianping, Doctor、Head of Neurology Department, Capital Medical University
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2015年10月1日
初级完成 (实际的)
2016年3月1日
研究完成 (实际的)
2016年5月1日
研究注册日期
首次提交
2016年2月24日
首先提交符合 QC 标准的
2016年2月26日
首次发布 (估计)
2016年2月29日
研究记录更新
最后更新发布 (实际的)
2020年5月12日
上次提交的符合 QC 标准的更新
2020年5月7日
最后验证
2020年5月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.